In the era of digitalisation and biosignatures, is C-reactive protein still the one to beat? - Authors' reply.

Autor: Kaforou M; Section of Paediatric Infectious Disease, Faculty of Medicine, Imperial College London, London, W2 1NY, UK; Centre for Paediatrics and Child Health, Imperial College London, London, W2 1NY, UK. Electronic address: m.kaforou@imperial.ac.uk., Jackson HR; Section of Paediatric Infectious Disease, Faculty of Medicine, Imperial College London, London, W2 1NY, UK; Centre for Paediatrics and Child Health, Imperial College London, London, W2 1NY, UK., Kuijpers TW; Sanquin Research and Landsteiner Laboratory, Department of Immunopathology, Sanquin Blood Supply, Amsterdam University Medical Center, Amsterdam, Netherlands; Department of Pediatric Immunology, Rheumatology and Infectious Diseases, Emma Children's Hospital, Amsterdam Amsterdam University Medical Center, Amsterdam, Netherlands., de Jonge MI; Department of Laboratory Medicine, Laboratory of Medical Immunology, Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands., Levin M; Section of Paediatric Infectious Disease, Faculty of Medicine, Imperial College London, London, W2 1NY, UK; Centre for Paediatrics and Child Health, Imperial College London, London, W2 1NY, UK.
Jazyk: angličtina
Zdroj: The Lancet. Digital health [Lancet Digit Health] 2024 Oct; Vol. 6 (10), pp. e678-e679.
DOI: 10.1016/S2589-7500(24)00178-X
Abstrakt: Competing Interests: All authors have filed a patent application for the six-protein signature discussed here.
Databáze: MEDLINE